Noticias

We just covered Cathie Wood’s 11 Biggest AI and Data Center Stock Picks. Tempus AI Inc. (NASDAQ:TEM) ranks #5 (see Cathie Wood’s 5 Biggest AI and Data Center Stock Picks). Cathie Wood’s Stake: $446,275,249 Tempus AI Inc. (NASDAQ:TEM) is an AI healthcare play in Cathie Wood’s portfolio. It’s a healthcare diagnostics and data platform that builds large-scale […]

Beneath the headline noise of a Q1 2026 beat and raised guidance, the critical insight for Tempus AI lies in a structural tug of war between an accelerating data moat and a currently elevated cost structure. The market is focusing on the 36% year over year top line growth to $348.1 million. The true alpha driver is hidden within the unit economics of the Data and Applications segment. This division is actively shifting the company from a traditional diagnostics provider to a recurring revenue he

Tempus (TEM) delivered earnings and revenue surprises of +38.10% and +0.75%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

In April 2026, the Keck School of Medicine of USC and Keck Medicine of USC announced a broad collaboration with Tempus AI to embed its genomic testing, AI tools, and data platform across more than 1.5 million annual patient visits in their Southern California network. This partnership not only expands Tempus AI’s clinical footprint but also deepens its access to real-world oncology data, reinforcing the company’s core data-network advantage in precision medicine. With this USC collaboration...

Fulgent Genetics (FLGT) delivered earnings and revenue surprises of -89.47% and +4.00%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

Is TEM a good stock to buy? We came across a bullish thesis on Tempus AI, Inc. on Joe Gannon’s Substack by Gannon Capital. In this article, we will summarize the bulls’ thesis on TEM. Tempus AI, Inc.’s share was trading at $56.78 as of April 20th. TEM’s trailing P/E was 39.30 according to Yahoo Finance. Tempus AI, Inc. operates as […]

TEM and ILMN battle in precision oncology, but stronger stock gains, valuation and earnings outlook position ILMN as the more compelling pick now.

The blended fair value estimate for Tempus AI has been adjusted slightly, moving from US$72.73 to US$72.40 as part of the latest round of analyst model updates. This small shift sits against a mixed research backdrop, where some firms are lifting targets after Q4 while others are trimming estimates and highlighting questions around data monetization, partnerships and the balance between growth and visibility. As you read on, you will see how to track these moving pieces and what to watch as...

TEM faces pressure ahead of Q1 earnings as macro headwinds, high valuation and estimate trends cloud its near-term investment appeal.